The USC Norris Comprehensive Cancer Center (NCCC) has a well-developed system for program planning and evaluation and uses several kinds of activities, supported in part by the CCSG Program Planning and Evaluation budget, to conduct its program planning and evaluation: meetings with its External Advisory Committee;offsite retreats for the overall Cancer Center Leadership plus invited guests and for specific programs;monthly meetings of the Executive Committee (the Director, Associate Directors, Medical Director of the Norris Cancer Hospital, and Chair of the Cancer Survivorship Advisory Council);and monthly meetings of the Cancer Center Leadership Council { .he Director, Associate Directors and Program Leaders). In compliance with the CCSG Guidelines, we plan to convene a meeting of our External Advisory Committee once a year. This will enable the EAC to be closely involved in our planning and implementation processes and better able to evaluate our accomplishments. We are requesting sufficient funds to bring each of them or a substitute ad hoc reviewer to the Cancer Center annually. We will continue to support our monthly Leadership Council dinner meetings to facilitate the scientific exchanges and program planning. We also plan to continue the biennial off-site Leadership Retreat in 2010 (with the current CCSG budget), 2012 and 2014. These retreats have been extremely valuable in setting the Cancer Center's scientific agenda, building camaraderie among Center leaders and encouraging collaborative inter-programmatic research. In the intervening years, we will support retreats for programs, either individually or jointly.

Public Health Relevance

The Planning and Evaluation Funds supports the strategic planning activities of the NCCC. The Cancer Center facilitates the discovery and development of more effective approaches to cancer prevention, diagnosis, and treatment, as well as deliver medical advances to patients and their families, educate health care professionals and the public, and reach out to underserved populations

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589339
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$66,924
Indirect Cost
$24,353
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121

Showing the most recent 10 out of 842 publications